Clinical Trial Update: A Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Therapy in Subjects With Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating UX003 rhGUS for MPS VII (Sly syndrome) has completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucopolysaccharidosis Vii
• Sly Syndrome

Drugs mentioned

• UX003 (recombinant human beta-glucuronidase)

Snippet

Sponsor: Ultragenyx Pharmaceutical Inc | Conditions: Sly Syndrome, MPS VII | Phase 3 | Status: COMPLETED | Results posted: 2019-07-30